MMWR. Recommendations and Reports:
December 16, 2005 / 54(RR15);49-55
Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes: implementation guidance
Автоматизированная технология амплификации нуклеиновых кислот в режиме реального времени для быстрого и одновременного выявления туберкулеза и устойчивости к р...ифампицину: система Xpert MTB/RIF.
Программное заявление.
more
One important application of digital health in TB patient care is the support that it can lend to medication adherence. TB programmes have already been using short message service (SMS), video-supported treatment (VOT) and event monitoring device for medication support ...(EMM)1 to help patients complete treatment and health-care workers to monitor both daily dosing and treatment continuity
more
Informe
Bogotá, 13-14 de abril del 2015
(actualizado en diciembre de 2014).
HIV/TB Research Meeting; March 3, 2013
Single TB and HIV Concept Note Albania 2016-2018 27 April 2015
NOVEMBER 2012
This document serves as an update to “Out of the Dark”, a report published by MSF in October 2011, highlighting the need to prioritise the long-neglected area of paediatric tuberculosis (TB). This update will outline the key improvements and setbacks—the ‘highlights’ and ‘...lowlights’—that have occurred over the last year.
more
This Rapid Communication aims to inform national TB programmes and other stakeholders about the key implications of the latest evidence on the use of specific molecular assays as initial diagnostic tests of pulmonary and extrapulmonary TB and RR-TB, in adults and children.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Regional Eastern European and Central Asian project (TB-REP) Copenhagen, Denmark, 26–28 April 2016
Version 1.0, 2014-11-21
Introduction:
This document lists TB indicators that can be derived from the recording and reporting tools defined
in Definitions and reporting framework for tuberculosis – 2013 revision (WHO/HTM/TB/2013.2).
Geneva, World Health Organization; 2013. (http://www.who.int/t...b/publications/definitions/en/).
More details on the rationale, calculation and use of these indicators are available in the following
publications:
• Understanding and using tuberculosis data (WHO/HTM/TB/2014.09). Geneva, World Health
Organization. 2014.
(http://www.who.int/tb/publications/understanding_and_using_tb_data/en/)
• Companion handbook to the WHO guidelines for the programmatic management of drugresistant
tuberculosis (WHO/HTM/TB/2014.11). Geneva, World Health Organization. 2014.
(http://www.who.int/tb/publications/pmdt_companionhandbook/en/)
• A guide to monitoring and evaluation for collaborative TB/HIV activities: 2014 revision. Geneva,
World Health Organization. 2014.
more
Alors que de nombreux pays touchés par le COVID-19 au cours des premiers mois de l'année commencent maintenant à assouplir les mesures de confinement à mesure que les taux d'infection et de mortalité diminuent, dans les régions les plus touchées par le VIH, la tuberculose et le paludisme, com...me l'Afrique, l'Asie du Sud et l'Amérique latine, la pandémie continue de s'accélérer. Dans les environnements à faibles ressources, les mesures de confinement sont moins efficaces et difficiles à maintenir, et les installations de soins cliniques sont extrêmement limitées. Dans de tels environnements, la réponse à COVID-19 doit se concentrer sur l'endiguement de la propagation de la pandémie par le dépistage, la recherche des contacts et l'isolement, la protection du personnel de santé par la formation et la fourniture d'équipements de protection individuelle (EPI) et la réduction de l'impact sur d'autres maladies par le renforcement des systèmes de santé fragiles et l'adaptation des programmes existants.
more
PLOS ONE | https://doi.org/10.1371/journal.pone.0210937
February 5, 2019